Inventiva is a clinical-stage company developing lanifibranor, an oral drug that activates all three PPAR receptors, for the fatty liver disease MASH; it is not approved.
Inventiva's case rests on lanifibranor, an oral pan-PPAR agonist with Breakthrough Therapy designation for MASH with moderate or advanced fibrosis. Topline results from the 1,009-patient Phase 3 NATiV3 are expected in the fourth quarter of 2026; Rezdiffra and Wegovy are already approved in the market it would enter. Cash of €233.9 million lasts only to the end of the second quarter of 2027; going further needs bonds available only if NATiV3 meets its primary endpoint.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: NATiV3 meets its primary endpoint
Does lanifibranor improve MASH and fibrosis over placebo at 72 weeks?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Inventiva expects NATiV3 Phase 3 topline results for lanifibranor in MASH in the fourth quarter of 2026; its current cash lasts to the end of the second quarter of 2027
Lanifibranor's NATiV3 Phase 3 readout in MASH will confirm or refute whether pan-PPAR agonism can compete in a market resmetirom now anchors
Lanifibranor's NATiV3 Phase 3 readout in MASH will determine whether Inventiva's pan-PPAR mechanism earns a place in a crowded, newly validated indication
Lanifibranor's NATiV3 Phase 3 readout in MASH will determine whether a pan-PPAR agonist can compete in a field already defined by resmetirom
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.